Exelixis Inc (EXEL) with a beta value of 0.52 appears to be a promising investment opportunity.

A new trading day began on Tuesday, with Exelixis Inc (NASDAQ: EXEL) stock price down -0.94% from the previous day of trading, before settling in for the closing price of $36.19. EXEL’s price has ranged from $19.20 to $36.60 over the past 52 weeks.

During the last 5-year period, the sales growth of Healthcare Sector giant was 17.31%. Meanwhile, its annual earnings per share averaged 156.75%. With a float of $278.37 million, this company’s outstanding shares have now reached $302.79 million.

Let’s determine the extent of company efficiency that accounts for 1310 employees. In terms of profitability, gross margin is 96.14%, operating margin of 25.92%, and the pretax margin is 29.7%.

Exelixis Inc (EXEL) Breakdown of a Key Holders of the stock

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Exelixis Inc is 2.52%, while institutional ownership is 85.93%. The most recent insider transaction that took place on Nov 05 ’24, was worth 3,394,510. In this transaction CSO/EVP Disc & Trans Research of this company sold 96,986 shares at a rate of $35.00, taking the stock ownership to the 498,945 shares. Before that another transaction happened on Nov 01 ’24, when Company’s EVP & General Counsel sold 50,000 for $34.13, making the entire transaction worth $1,706,500. This insider now owns 530,325 shares in total.

Exelixis Inc (EXEL) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around 156.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.96% during the next five years compared to -21.77% drop over the previous five years of trading.

Exelixis Inc (NASDAQ: EXEL) Trading Performance Indicators

Here are Exelixis Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.88. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.92. Likewise, its price to free cash flow for the trailing twelve months is 23.66.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.57, a number that is poised to hit 0.38 in the next quarter and is forecasted to reach 1.64 in one year’s time.

Technical Analysis of Exelixis Inc (EXEL)

Looking closely at Exelixis Inc (NASDAQ: EXEL), its last 5-days average volume was 2.02 million, which is a drop from its year-to-date volume of 2.07 million. As of the previous 9 days, the stock’s Stochastic %D was 90.26%. Additionally, its Average True Range was 0.94.

During the past 100 days, Exelixis Inc’s (EXEL) raw stochastic average was set at 94.93%, which indicates a significant increase from 91.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.55% in the past 14 days, which was higher than the 36.17% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $28.48, while its 200-day Moving Average is $24.18. However, in the short run, Exelixis Inc’s stock first resistance to watch stands at $36.29. Second resistance stands at $36.73. The third major resistance level sits at $36.97. If the price goes on to break the first support level at $35.61, it is likely to go to the next support level at $35.37. Now, if the price goes above the second support level, the third support stands at $34.93.

Exelixis Inc (NASDAQ: EXEL) Key Stats

With a market capitalization of 10.24 billion, the company has a total of 285,579K Shares Outstanding. Currently, annual sales are 1,830 M while annual income is 207,770 K. The company’s previous quarter sales were 539,540 K while its latest quarter income was 117,970 K.